Germany based Merck has formed a global fertility alliance with llumina and Genea to excel in Assisted Reproductive Treatment (ART) through collaborative approach.

The alliance will try to identify, assess and work on fertility-related laboratory processes, co-ordinate to improve consistency in ART worldwide and is likely to be a solution for the standardisation requirements of fertility processes within the ART laboratory.

It is in line with Merck's business strategy which aims at setting global standards in the fertility technologies and help families to have babies.

Merck biopharmaceuticals business unit Global Strategy and Franchises head Meeta Gulyani said: "We are the global leader in the field of fertility drugs and committed to supporting the success and improvement in ART by going beyond drugs with innovative technologies.

"By forging the Global Fertility Alliance with partners like Illumina and Genea we aim to support the development of needed global standards in ART labs. This will ensure a consistently high level of performance between different centers and countries."

Genea CEO Tomas Stojanov said: "Increasing success rates for patients worldwide and advancing the science of fertility treatment is an integral part of our mission.

"The new Global Fertility Alliance for excellence in ART will drive automation and standardization in the field and support health care professionals in providing their patients with the best possible outcomes."